Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-IL4/IL13 Therapy With Dupilumab for Prevention of Refractory Chronic Rhinosinusitis After Endoscopic Sinus Surgery for CRSwNP

NCT04596189 is registered in ClinicalTrials.gov with Centre hospitalier de l'Université de Montréal (CHUM) as lead sponsor.

NCT NCT04596189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04596189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-IL4/IL13 Therapy With Dupilumab for Prevention of Refractory Chronic Rhinosinusitis After Endoscopic Sinus Surgery for CRSwNP
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Phase
Phase 4
Overall status
Completed
Start date
May 25, 2021
Completion date
April 23, 2024
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis with nasal polyps